CASI News and Press, CASI Pharmaceuticals Inc. From 08/11/23

2023-08-11 07:45:03 ET CASI Pharmaceuticals press release ( NASDAQ: CASI ): Q2 GAAP EPS of -$0.77. Revenue of $9.82M (+14.6% Y/Y). As of June 30, 2023, CASI had cash, cash equivalents and short-term investments of $36.8 million. For further details see: CASI ...

CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2023 BUSINESS AND FINANCIAL UPDATES PR Newswire BEIJING , Aug. 11, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing and commercializing innovative thera...

Mundipharma International Corporation Limited, Mundipharma Medical Company, and Acrotech Biopharma Inc. Enter Agreement to Transfer License of FOLOTYN® (Pralatrexate) in China to CASI Pharmaceuticals PR Newswire BEIJING , Aug. 1, 2023 /PRNewswire/ -- CASI Ph...

2023-07-23 05:45:00 ET Summary Novartis has signed a $1 billion deal to acquire DTx Pharma - DTx Pharma shareholders will receive $500 million upfront and up to $500 million in milestones. Sichuan Kelun-Biotech completed a $174 million IPO on the Hong Kong Exchange, valuing the co...

CASI Pharmaceuticals Acquires Global Intellectual Property Rights to Cleave Therapeutics' VCP/P97 Inhibitor CB-5339 PR Newswire BEIJING , July 20, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company focused on developing an...

2023-05-17 08:06:14 ET CASI Pharmaceuticals press release ( NASDAQ: CASI ): Q1 GAAP EPS of -$0.45. Revenue of $8.35M (-7.8% Y/Y). For further details see: CASI Pharmaceuticals GAAP EPS of -$0.45, revenue of $8.35M

CASI PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2023 FINANCIAL RESULTS PR Newswire BEIJING , May 17, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman Islands incorporated biopharmaceutical company focused on developing and commercializing...

2023-04-26 13:30:58 ET CASI Pharmaceuticals press release ( NASDAQ: CASI ): Q4 GAAP EPS of -$3.01 misses by $2.64 . Revenue of $43.12M beats by $32.31M . For further details see: CASI Pharmaceuticals GAAP EPS of -$3.01 misses by $2.64, revenue of $43.12M ...

CASI Pharmaceuticals Files Annual Report on Form 20-F for Fiscal Year 2022 PR Newswire BEIJING , April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (NASDAQ: CASI) ("CASI" or the "Company"), a biopharmaceutical company focused on developing and commerc...

CASI PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2022 FINANCIAL RESULTS PR Newswire BEIJING , April 26, 2023 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a Cayman incorporated biopharmaceutical company focused on developing and commercial...